Skip to main content

Actors and Networks database

The evolving field of gene and cell therapy is supported by a large community of academic, clinical, translational, regulatory and patient organisations. The Actors and Networks database maps these stakeholders in Europe and beyond, their activities, and resources they have produced. 

EuroGCT has developed and compiled this database for those interested in identifying the actors involved at each stage of the pathways bringing gene and cell therapies from lab to clinic. Coming from an academic perspective, our focus is to map information that has not been mapped elsewhere. This includes documenting the various types of interconnected regulators, patient groups actively involved along the pathways, and non-profit organisations devoted to therapy development. In its first iteration, this database does not yet include commercial partners and service providers.

Additional complementary work by other organisations on GCT stakeholders mapping can be found here.

A scientific paper on actors has also been published in Humanities and Social Sciences Communications. You can find its lay summary here.

Showing 10 of 372

Swiss Federal Office for the Environment (Bundesamt für Umwelt / Office fédéral de l'environnement / Ufficio federale dell'ambiente) (FOEN / BAFU / OFEV / UFAM)

Type of Actor:

  • Regulators
  • Other National competent authorities
  • Competent Authorities for GMO

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Manufacturing
  • Commercialisation

Swiss Federal Office of Public Health – Division of Biomedicine Biosafety, Human Genetics and Reproductive Medicine Section (FOPH / BAG / OFSP)

Region/Country:  
  • Other region/country

Type of Actor:

  • Regulators
  • Other National competent authorities
  • Competent Authorities for Tissues and Cells
  • Competent Authorities for Blood and Blood Components
  • Competent Authorities for GMO

Development Stage:

  • Fundamental Research
  • Translational Research
  • Clinical Research
  • Manufacturing
  • Commercialisation

SZUTEST Konformitätsbewertungsstelle GmbH

Region/Country:  
  • Countries in the EU/EEA
  • Germany

Type of Actor:

  • Regulators
  • Medical Devices Entities
  • Notified Bodies

Development Stage:

  • Manufacturing
  • Commercialisation

T2Evolve (T2Evolve)

Region/Country:  
  • EU/EEA

Type of Actor:

  • Networks
  • EU Research Projects

Development Stage:

  • Clinical Research
  • Translational Research
  • Commercialisation
  • Patient and Public Involvement

Conditions and Diseases:

  • Cancer
  • Blood disorders

Additional information

T2Evolve is a consortium working to accelerate the process of developing CAR T-cell therapy in the EU.

Thalassaemia International Federation (TIF)

Region/Country:  
  • Global

Type of Actor:

  • Patient Organisations
  • International Patient Organisations

Development Stage:

  • Patient and Public Involvement

Conditions and Diseases:

  • Blood disorders

Additional information

The Thalassaemia International Federation is a non-profit, non-governmental umbrella organisation that brings together national thalassaemia and other disease-specific patient associations, health-related organisations and institutions, pharmaceutical companies, health professionals and individuals from across the world.

The Cell and Gene Therapy Catapult (CGT Catapult)

Region/Country:  
  • UK

Type of Actor:

  • Non-profit Research Organisations
  • Translational Centres

Development Stage:

  • Translational Research
  • Manufacturing
  • Commercialisation

Additional information

The CGT Catapult is an independent not-for-profit innovation and technology organisation committed to the advancement of cell and gene therapies.

The Centre for Cardiovascular Science, The University of Edinburgh (CVS)

Region/Country:  
  • UK

Type of Actor:

  • Non-profit Research Organisations
  • Academic Bodies

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Patient and Public Involvement

Conditions and Diseases:

  • Heart disease

Additional information

CVS is a world-leading centre of excellence that integrates discovery, translational and clinical cardiovascular research to transform the diagnosis, treatment and management of people with heart and circulatory diseases.

The European Association Medical devices of Notified Bodies (Team-NB)

Region/Country:  
  • EU/EEA

Type of Actor:

  • Regulators
  • Medical Devices Entities
  • Medical Device Authorities
  • Supranational Medical Device Authorities

Development Stage:

  • Clinical Research
  • Manufacturing
  • Commercialisation

The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT)

Region/Country:  
  • EU/EEA
  • UK

Type of Actor:

  • Networks
  • European and Regional Networks

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Manufacturing
  • Commercialisation
  • Patient and Public Involvement
  • Health Data

Additional information

EuroGCT brings together 47 partner organisations and institutions across Europe with a goal of providing reliable and accessible information about the use of cells and genetic material to treat disease.

Resources

Resources on gene and cell therapy development: https://www.eurogct.org/research-pathways; Educational resources: https://www.eurogct.org/discover-gene-and-cell-therapy/educational-resources-directory; Patient and Public Involvement resources: https://www.eurogct.org/atmp-engage; accessible information about the science behind gene and cell therapies: https://www.eurogct.org/discover-gene-and-cell-therapy

The Fraunhofer Institute for Biomedical Engineering (Fraunhofer IBMT)

Region/Country:  
  • Countries in the EU/EEA
  • Germany

Type of Actor:

  • Non-profit Research Organisations
  • Academic Bodies

Development Stage:

  • Fundamental Research
  • Manufacturing

Additional information

Fraunhofer IBMT has been working in the field of stem cell research and hosting extensive cell line stocks in industrial and clinically structured biobanks for low temperature storage of valuable samples (fluids, cells, tissue fragments).
Did you find the content on this page useful? If not, you can leave us a message so we can improve Send us your thoughts